Trial · NCT00884221
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Ongoing Pregnancy After One Fresh Embryo Replacement Cycle, Intention-to-treat (ITT) Analysis Set | 10-11 weeks after embryo transfer at the blastocyst stage | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | Percentage of participants | MEAN |
| SECONDARY | Endocrine Profile (Estradiol), Intention-to-treat (ITT) Analysis Set | On the last day of stimulation, blood was drawn at least 8 hours after the previous injection of gonadotrophin and GnRH antagonist | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | pmol/L | MEAN |
| SECONDARY | Endocrine Profile (FSH), Intention-to-treat (ITT) Analysis Set | On the last day of stimulation, blood was drawn at least 8 hours after the previous injection of gonadotrophin and GnRH antagonist | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | IU/L | MEAN |
| SECONDARY | Endocrine Profile (Free Androgen Index), Intention-to-treat (ITT) Analysis Set | On the last day of stimulation, blood was drawn at least 8 hours after the previous injection of gonadotrophin and GnRH antagonist | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | Percentage of participants | MEAN |
| SECONDARY | Endocrine Profile (Luteinizing Hormone), Intention-to-treat (ITT) Analysis Set | On the last day of stimulation, blood was drawn at least 8 hours after the previous injection of gonadotrophin and GnRH antagonist | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | IU/L | MEAN |
| SECONDARY | Endocrine Profile (Progesterone), Intention-to-treat (ITT) Analysis Set | On the last day of stimulation, blood was drawn at least 8 hours after the previous injection of gonadotrophin and GnRH antagonist | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | nmol/L | MEAN |
| PRIMARY | Ongoing Pregnancy After One Fresh Embryo Replacement Cycle, Per-protocol (PP) Analysis Set | 10-11 weeks after embryo transfer at the blastocyst stage | The per-protocol (PP) analysis set was defined as all randomized and exposed participants except those excluded as a result of major protocol deviations, such as significant non-compliance or other serious unforeseen deviations deemed to invalidate the data and affect the conclusions of the trial. | Percentage of participants | MEAN |
| SECONDARY | Endocrine Profile (Prolactin), Intention-to-treat (ITT) Analysis Set | On the last day of stimulation, blood was drawn at least 8 hours after the previous injection of gonadotrophin and GnRH antagonist | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | pmol/L | MEAN |
| SECONDARY | Endocrine Profile (Sex Hormone Binding Globulin), Intention-to-treat (ITT) Analysis Set | On the last day of stimulation, blood was drawn at least 8 hours after the previous injection of gonadotrophin and GnRH antagonist | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | nmol/L | MEAN |
| SECONDARY | Endocrine Profile (Testosterone), Intention-to-treat (ITT) Analysis Set | On the last day of stimulation, blood was drawn at least 8 hours after the previous injection of gonadotrophin and GnRH antagonist | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | nmol/L | MEAN |
| SECONDARY | Number of Follicles of >= 12mm, 12-14 mm, 15-16 mm and >= 17 mm in Each Participant, Intention-to-treat (ITT) Analysis Set | Last stimulation day | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | Follicles per participant | MEAN |
| SECONDARY | Number of Oocytes Retrieved in Each Participant, Intention-to-treat (ITT) Analysis Set | 36 h after hCG | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | Oocytes per participant | MEAN |
| SECONDARY | Fertilization, Intention-to-treat (ITT) Analysis Set | 1 day after oocyte retrieval (19 h post-insemination) | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | Percentage of metaphase II oocytes | MEAN |
| SECONDARY | Blastocyst Quality, Intention-to-treat (ITT) Analysis Set | 5 days after oocyte retrieval (120h post-insemination) | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | Number of blastocysts | MEAN |
| SECONDARY | Live Birth for a Single Stimulation Cycle With Single Blastocyst Transfer From Fresh Embryo Replacement Cycle, Intention-to-treat (ITT) Analysis Set | Post-trial information | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | Percentage of participants | MEAN |
| SECONDARY | Cumulative Live Birth for a Single Stimulation Cycle With Single Blastocyst Transfer From Fresh and 1 Year Frozen Embryo Replacement Cycles, Intention-to-treat (ITT) Analysis Set | Post-trial information | The intention-to-treat (ITT) analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment. | Percentage of participants | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00884221/outcomes